The Abu Dhabi declaration: why the hustle?

Dr. Azim is Professor of Clinical Oncology at Cairo University in Egypt. His interests lie in lymphoma, breast cancer, bone metastases, and translational research, and has published more than 50 papers and 100 abstracts. Dr. Azim is a member of numerous societies, including ASCO and ASH. He sits on several scientific committees and has been an invited speaker to more than 100 regional and international conferences in the Middle East, Europe, United States, and Asia, and has published more than 50 papers and 100 abstracts. The Abu Dhabi Declaration: Why the Hustle?

[1]  H. Azim,et al.  Review article optimizing the use of her-2/neu targeting agents in breast cancer : a developing nation perspective. , 2007, Journal of the Egyptian National Cancer Institute.

[2]  M. Colombo,et al.  High prevalence of multinodular hepatocellular carcinoma in patients with cirrhosis attributable to multiple risk factors , 1999, Hepatology.

[3]  I. Ruczinski,et al.  The Association between Skin Characteristics and Skin Cancer Prevention Behaviors , 2009, Cancer Epidemiology, Biomarkers & Prevention.

[4]  Elsayed I Salim,et al.  Cancer epidemiology and control in the arab world - past, present and future. , 2009, Asian Pacific journal of cancer prevention : APJCP.

[5]  A. Younis,et al.  Time-trend in epidemiological and pathological features of schistosoma-associated bladder cancer. , 2008, Journal of the Egyptian National Cancer Institute.

[6]  L. Tanoue,et al.  Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma , 2010 .

[7]  M. Seoud,et al.  Trends in epidemiology and management of breast cancer in developing Arab countries: a literature and registry analysis. , 2007, International journal of surgery.

[8]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[9]  M. Wilson,et al.  Epidemiology of hepatitis viruses among hepatocellular carcinoma cases and healthy people in Egypt: A systematic review and meta‐analysis , 2009, International journal of cancer.

[10]  J. Minna,et al.  Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.

[11]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.